» Articles » PMID: 20827273

Interleukin-1 Receptor Activation by Systemic Lipopolysaccharide Induces Behavioral Despair Linked to MAPK Regulation of CNS Serotonin Transporters

Overview
Date 2010 Sep 10
PMID 20827273
Citations 140
Authors
Affiliations
Soon will be listed here.
Abstract

Serotonin (5-hydroxytryptamine, 5-HT) has long been implicated in regulation of mood. Medications that block the neuronal 5-HT transporter (SERT) are used as major pharmacological treatment for mood disorders. Conversely, stimuli that enhance SERT activity might be predicted to diminish synaptic 5-HT availability and increase the risk for 5-HT-related CNS disorders. We have shown that the inflammatory cytokines enhance brain SERT activity in cultured serotonergic cells and nerve terminal preparations in vitro. In this study, we establish that intraperitoneal injection of the cytokine-inducer lipopolysaccharide (LPS) stimulates brain SERT activity, acting at doses below those required to induce overt motor suppression. SERT stimulation by LPS is paralleled by increased immobility in both the tail suspension test (TST) and the forced swim test (FST); antidepressant-sensitive alterations are thought to model aspects of behavioral despair. Both the stimulation of SERT activity and induced immobility are absent when LPS is administered to interleukin-1 receptor (IL-1R)-deficient mice and in the presence of SB203580, an inhibitor of IL-1R-stimulated p38 MAPK. Moreover, the ability of LPS to enhance immobility in TST is lost in SERT knockout mice. These findings reveal an ability of peripheral inflammatory stimuli to enhance brain SERT activity through IL-1R and p38 MAPK pathways in vivo and identify a requirement for SERT expression in immune-system-modulated despair behaviors. Our studies identify IL-1R- and p38 MAPK-dependent regulation of SERT as one of the mechanisms by which environmentally driven immune system activation can trigger despair-like behavior in an animal model, encouraging future analysis of the pathway for risk factors in neuropsychiatric disorders.

Citing Articles

Flavins and Flavoproteins in the Neuroimmune Landscape of Stress Sensitization and Major Depressive Disorder.

Schrier M, Smirnova M, Nemeth D, Deth R, Quan N J Inflamm Res. 2025; 18:681-699.

PMID: 39839188 PMC: 11748166. DOI: 10.2147/JIR.S501652.


Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome.

Deng H, Chen Y, Xing J, Zhang N, Xu L Front Immunol. 2025; 15:1470283.

PMID: 39749338 PMC: 11693511. DOI: 10.3389/fimmu.2024.1470283.


Lipopolysaccharide Effects on Neurotransmission: Understanding Implications for Depression.

Batey L, Baumberger B, Khoshbouei H, Hashemi P ACS Chem Neurosci. 2024; 15(24):4339-4347.

PMID: 39601433 PMC: 11660149. DOI: 10.1021/acschemneuro.4c00591.


Localization of brain neuronal IL-1R1 reveals specific neural circuitries responsive to immune signaling.

Nemeth D, Liu X, Monet M, Niu H, Maxey G, Schrier M J Neuroinflammation. 2024; 21(1):303.

PMID: 39563437 PMC: 11575132. DOI: 10.1186/s12974-024-03287-1.


Association between Inflammatory and Metabolic Biomarkers and Common Mental Disorders among Adults: 2015 Health Survey of São Paulo, SP, Brazil.

Ferreira L, Fisberg R, Sarti F, Rogero M Metabolites. 2024; 14(10).

PMID: 39452916 PMC: 11509269. DOI: 10.3390/metabo14100535.


References
1.
Castanon N, Bluthe R, Dantzer R . Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl). 2001; 154(1):50-60. DOI: 10.1007/s002130000595. View

2.
Yirmiya R . Endotoxin produces a depressive-like episode in rats. Brain Res. 1996; 711(1-2):163-74. DOI: 10.1016/0006-8993(95)01415-2. View

3.
Ozaki N, Goldman D, Kaye W, Plotnicov K, Greenberg B, Lappalainen J . Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry. 2003; 8(11):933-6. DOI: 10.1038/sj.mp.4001365. View

4.
Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R . Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv Exp Med Biol. 1999; 461:283-316. DOI: 10.1007/978-0-585-37970-8_16. View

5.
Konsman J, Veeneman J, Combe C, Poole S, Luheshi G, Dantzer R . Central nervous action of interleukin-1 mediates activation of limbic structures and behavioural depression in response to peripheral administration of bacterial lipopolysaccharide. Eur J Neurosci. 2008; 28(12):2499-510. DOI: 10.1111/j.1460-9568.2008.06549.x. View